Member Info for alfista

How do we get to big profitability?
Someone with big resources commercialises the health benefits to the extent that Fruitflow becomes a household name across a huge sector of middle to higher income consumers, in the main consumer markets globally.
If, (or when) that happens then that graph would have to be expanded IMHO

Not a surprise to me, been saying it for a while.
Dear old Saloni, o0ne of the older brands, it's a pity for their employees, but they're not alone.

The sp helps me sleep better
:-)

There was zero research back then on gut biota, that has only just been identified, and has yet to be patented, approved etc etc

Perhaps the chartists amongst us could study the Bristol Stool Chart and predict the future sp.?

Seriously though, it does indicate that the users of Fruitflow have been receiving bonus health benefits not identified before. Very good news.

Good find Doc.
Shows some commitment to the massive gut health sector, with Fruitflow at the centre of their scientific studies.

It'll be the notified amount. If it were more they'd have to issue an RNS

So, there you have it, MSG frozen out by the other holders.
They've made their wishes very clear, so they'll have to bear the consequences.

There has been ample opportunity to adjust your holding while the price was much lower than todays.
These " it's the only investment cash I ever had" claims do get a bit wearying. Did so few people really take no notice of the involvement of the backers who reversed the decline a few years back? I saw great significance in the involvement of Stuey Luey, bless his cotton socks.

So, if you'd like to assume that the BoD are successful in defeating their main shareholder's wishes, what happens next? If they have already started a process of building a new brand in the UK, would they not seek to fund that in part by releasing cash from their holding in this company? If they did that at a rapid rate, things could turn nasty quite quickly.
Couldn't they?

Direct sales also begin this month to Fruitflow brand users.
Invoice financing is another option, quite straightforward, but involving some loss of margin.
Options.

They have a couple of other options, such as stock financing (overdraft), and logistics funding, (third party handler)

No.
Read the rest of the update and you will see that they have enough cash to cover at least two of the payments, and that there are other funding options.

Didn't need to.
The issue with scientific products is that their creators are so enamoured with the ability to control a specific body function that they are prepared to overlook known adverse effects IMHO. Having a product here that has no such adverse effects should benefit us greatly, except that the industry has far more resources to keep control of the narrative. However, there must be enough educated consumers who can differentiate. If only we can reach them.

Whatever the cause, excess myocarditis is a factor worthy of much discussion. The US bloggers are all over it, but it seems big pharma were handed a free pass.
Then again, Bern says we have to accept the science, gawd I wish I had a quid for every time I've read that.

"The important thing is not to stop questioning. Curiosity has its own reason for existing" Albert Einstein.
" If its settled it isn't science, and if it's science, it isn't settled" Michael Crichton

Perhaps, but, as with most things scientific these days, someone who raises a matter which doesn't conform to the "consensus" is subject to a quick pile on of disapproval. His paper is out there, and there are a number of others who are reporting on the adverse effects, and seeking an explanation of the higher than normal incidence of cardiac inflammation.
The argument has rapidly vanished that the stuff is fully safe in all circumstances. Whether or not it will be proven to have been more bad than good will not be obvious for years IMHO.

With Fruitflow, every single trial has not thrown up any side effects at all. I really appreciate that.

Watched a Youtube interview with Dr Aseem Malhotra recently. His studies of Covid treatments, and mistakes made during the pandemic, is fascinating. It strongly suggests a mindset of greed by pharma, and many medics, means that they give little regard to efficacy, and far too much emphasis on profits. It's sad, but I do think that individuals should always study their own path to general health. Isn't that why we all chose to take Fruitflow in the first place, and lots of us have experienced really important benefits.

Not had.
Fingers crossed

A fair few valid points there.
FF as a drug would require large investment, you might read in to that By Health are the only candidate to fund it, why would they not acquire the whole company before committing those levels of funding?
DS/PX transfer, you can read the terms in the RNS, so the answer is No.
China has been in weird territory throughout 2022, lockdowns and business disruption. I imagine that could have affected data collection.
Expanding FF+O3 sales. That will require a sales network/more staff etc. Not fundable at present perhaps?
I think we have to accept that the Liverpool work will remain academic. so of little value to us
Blood pressure patent, air pollution effects patent. One word. Funding

The new era should be as you say, but it seems to me that we are constrained by careful spending until revenues flow from the newly started collaboration with By Health.

Stability is more important IMHO. The update didn't address the uncertainty over whether or not more funding is needed, my hunch is that it is, but that the support will be there for it. Until we know, hands are being sat on. Also, I reckon most ISA's are maxed out until the next tax year, and that puts a further brake on trades.